Financials data is unavailable for this security.
View more
Year on year Torrent Pharmaceuticals Ltd grew revenues 11.51% from 96.20bn to 107.28bn while net income improved 33.02% from 12.45bn to 16.56bn.
Gross margin | 75.52% |
---|---|
Net profit margin | 16.06% |
Operating margin | 24.80% |
Return on assets | 12.08% |
---|---|
Return on equity | 25.37% |
Return on investment | 17.95% |
More ▼
Cash flow in INRView more
In 2024, Torrent Pharmaceuticals Ltd increased its cash reserves by 64.23%, or 3.27bn. The company earned 32.66bn from its operations for a Cash Flow Margin of 30.44%. In addition the company used 1.68bn on investing activities and also paid 27.80bn in financing cash flows.
Cash flow per share | 76.84 |
---|---|
Price/Cash flow per share | 41.64 |
Book value per share | 221.72 |
---|---|
Tangible book value per share | 83.65 |
More ▼
Balance sheet in INRView more
Current ratio | 1.21 |
---|---|
Quick ratio | 0.7444 |
Total debt/total equity | 0.4166 |
---|---|
Total debt/total capital | 0.2941 |
More ▼
Growth rates in INR
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 27.27% and 33.02%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked above the industry average relative to its peers.
Div yield(5 year avg) | 1.19% |
---|---|
Div growth rate (5 year) | 26.93% |
Payout ratio (TTM) | 11.27% |
EPS growth(5 years) | 30.58 |
---|---|
EPS (TTM) vs TTM 1 year ago | 34.13 |
More ▼